Puma Biotechnology, Inc.
Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology | Business Wire
PUMA BIOTECHNOLOGY, INC. FORM 10-K - Biotech Due Diligence
PUMA BIOTECHNOLOGY, INC. : PBYI Stock Price | US74587V1070 | MarketScreener
Former Puma Biotech Executive Gets U.S. Prison Term for Insider Trading
Puma Biotechnology Inc Share Price USD0.0001
Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology | Business Wire
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire
Puma Biotechnology, Inc. - SEC Filings - Annual Reports & Proxies
Puma Biotechnology Presents Outcomes from the Metastatic Breast Cancer Cohort of the SUMMIT Trial at the ASCO 2022 Annual Meeting
Pint-Pharma - Puma Biotechnology and Pint Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin America
Federal Jury Awards Puma Biotechnology Investors Damages in Securities Class-Action Verdict - Los Angeles Business Journal
Chris Culotta - Associate Director, Accounting - Puma Biotechnology, Inc. | LinkedIn
Puma Biotechnology
Puma Biotechnology, Inc. | CDISC
PUMA BIOTECHNOLOGY INC - COMMON STOCK 1 Full Quote | NetDania.com
PUMA BIOTECHNOLOGY, INC. FORM 10-K - Biotech Due Diligence
Puma Biotechnology, Inc. | LinkedIn
Puma Biotechnology, Inc. | LinkedIn
Pamela Wilson email address & phone number | Puma Biotechnology, Inc. Sr VP, Clinical Operations contact information - RocketReach
